Antisense RNAi Therapeutics Market Size, Share and Forecast 2032

Market Overview:

The global antisense and RNAi therapeutics market was valued at USD 4,719 million in 2024 and is projected to reach USD 18,373 million by 2032, expanding at a CAGR of 18.52% during the forecast period.

The top players in the antisense and RNAi therapeutics market include Ionis Pharmaceuticals, Inc., Olix Pharmaceuticals, Inc., Sanofi, Benitec Biopharma Inc., Percheron Therapeutics Limited, Alnylam Pharmaceuticals, Inc., GSK plc, Silence Therapeutics, Sarepta Therapeutics, and Arbutus Biopharma. These companies lead through robust R&D pipelines, strategic collaborations, and multiple RNA-based drugs targeting genetic, rare, and oncological diseases. North America dominated the global market with a 44.6% share in 2024, supported by advanced healthcare infrastructure and strong clinical activity. Europe followed with a 29.3% share due to regulatory support for RNA therapies, while Asia-Pacific accounted for 20.8%, driven by rapid biotech growth and expanding genomic research capabilities.

Market Insights

• The global antisense and RNAi therapeutics market was valued at USD 4,719 million in 2024 and is projected to reach USD 18,373 million by 2032, growing at a CAGR of 18.52% during the forecast period.
• Rising prevalence of genetic and rare diseases, along with increasing FDA approvals of RNA-based drugs, drives strong market expansion, with RNA interference technology holding a 62.4% share in 2024 due to its high specificity and efficacy.
• Key trends include advancements in lipid nanoparticle and conjugate delivery systems that improve RNA stability, bioavailability, and targeted therapeutic outcomes across various indications.
• Leading players such as Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sanofi, and GSK focus on partnerships, pipeline diversification, and precision medicine strategies to strengthen their global presence and accelerate commercialization.
• North America dominated the market with a 44.6% share in 2024, followed by Europe with 29.3% and Asia-Pacific with 20.8%, supported by expanding biotechnology research and clinical adoption.

Market Segmentation Analysis:

By Technology

In the technology segment, the RNA interference (RNAi) sub-segment dominated the antisense and RNAi therapeutics market with a 62.4% share in 2024. This dominance is driven by RNAi’s high target specificity, strong efficacy, and growing number of approved siRNA-based drugs. Advancements in delivery platforms such as lipid nanoparticles have improved RNA stability and bioavailability. The technology’s success in treating rare genetic and hepatic disorders strengthens its leadership. The antisense RNA segment follows, supported by its established clinical record and expanding applications in neurological and metabolic diseases.

• For instance, Alnylam Pharmaceuticals, Inc.'s AMVUTTRA® (vutrisiran) achieved U.S. FDA approval in June 2022 for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, as the fifth RNAi therapeutic developed by the company, following ONPATTRO®, GIVLAARI®, OXLUMO®, etc..

By Application

The genetic disease segment held the largest market share of 45% in 2024, making it the leading application area for antisense and RNAi therapeutics. The segment benefits from rising prevalence of hereditary disorders and growing acceptance of RNA-based precision medicine. Increasing approvals of drugs targeting conditions such as spinal muscular atrophy and transthyretin amyloidosis drive adoption. Expanding research on rare and orphan diseases further accelerates the demand for targeted RNA-based interventions, while oncology and infectious diseases represent fast-growing secondary application areas.

• For instance, Ionis Pharmaceuticals, Inc. reported positive data from its Phase 2 study of IONIS-GCGR Rx in 79 type 2 diabetes patients, showcasing the company’s antisense platform expanding beyond neurology into metabolic disease.

By Route of Administration

The intravenous injection segment led the market with a 42.7% share in 2024, supported by its proven ability to ensure systemic distribution and high bioavailability for RNA-based drugs. Intravenous routes are widely used in hospital and clinical settings for therapies targeting liver and blood-related genetic disorders. Advancements in infusion formulations and carrier technologies enhance the delivery efficiency of RNA molecules. Meanwhile, subcutaneous and intrathecal routes are gaining traction for chronic and neurological treatments, providing patients with improved convenience and localized therapeutic control.

Key Growth Drivers

Advancements in RNA-Based Drug Delivery Technologies

Ongoing innovation in delivery systems such as lipid nanoparticles (LNPs), conjugates, and viral vectors is transforming the efficacy and stability of RNA-based drugs. These technologies improve cellular uptake, enhance target precision, and minimize off-target effects. Enhanced delivery also broadens the therapeutic scope beyond hepatic diseases to neurological and oncological disorders. Pharmaceutical companies are increasingly investing in next-generation delivery platforms to extend the clinical success of antisense and RNAi molecules, significantly accelerating commercialization and expanding market penetration across multiple therapeutic areas.

• For instance, Moderna developed a proprietary LNP platform used in numerous clinical-stage RNA therapeutics, which, through encapsulation, protects the fragile mRNA from rapid degradation by extracellular ribonucleases in the body.

Rising Prevalence of Genetic and Rare Diseases

The growing incidence of genetic and rare disorders globally is a major factor driving demand for antisense and RNAi therapies. These therapeutics directly target defective mRNA, enabling precise correction of genetic dysfunctions at the molecular level. Increasing awareness, coupled with expanded diagnostic capabilities, enhances early detection and treatment adoption. Strong regulatory incentives such as orphan drug designations and fast-track approvals also encourage R&D investment. As a result, more RNA-based drugs are progressing through clinical pipelines, fueling overall market growth.

• For instance, Wave Life Sciences’ stereopure oligonucleotide platform demonstrated over 90% allele-selective silencing efficiency in Huntington’s disease preclinical models.

Increased Investment and Strategic Collaborations

Pharmaceutical and biotechnology firms are actively partnering to accelerate RNA therapeutics development. Collaborations between major players such as Alnylam, Ionis, and Novartis have driven innovation in gene-silencing mechanisms and expanded global manufacturing capacity. Venture capital funding and government grants are supporting startups specializing in RNA drug discovery. These partnerships not only streamline clinical trials but also improve market access and technology sharing. The resulting synergy is fostering a strong competitive landscape that promotes large-scale commercialization and faster regulatory approvals worldwide.

Key Trends and Opportunities

Expansion into Oncology and Infectious Diseases

RNA-based therapeutics are moving beyond rare and genetic disorders into oncology and viral infections. The technology’s ability to silence oncogenes and modulate immune pathways positions it as a next-generation cancer treatment approach. Clinical trials targeting liver, lung, and hematologic malignancies are increasing rapidly. Similarly, RNAi mechanisms show strong potential in combating viral infections such as hepatitis B and emerging pathogens. This expansion diversifies the market and enhances long-term growth opportunities across a wider therapeutic spectrum.

• For instance, Arrowhead Pharmaceuticals reported a maximum reduction of 5.0 log₁₀ in HBsAg levels in a Phase 2 study of their RNAi therapy ARC-520 for chronic hepatitis B.

Emergence of Personalized and Precision Medicine

Personalized medicine is a key opportunity area, as RNA-based drugs allow customization based on a patient’s genetic profile. Advancements in sequencing technologies enable rapid identification of target mutations, facilitating the development of individualized therapies. Companies are leveraging bioinformatics and AI to design RNA molecules that specifically modulate patient-specific genes. This trend improves therapeutic efficacy, reduces adverse reactions, and aligns with the global shift toward precision healthcare, making antisense and RNAi platforms integral to next-generation treatment strategies.

• For instance, Sirnaomics dosed the first patient in their Phase I/II trial of STP705-an siRNA therapeutic targeting TGF-β1 and COX-2-for facial squamous cell carcinoma in situ, utilising a three-cohort escalation of 30 µg, 60 µg and 90 µg weekly doses in 30 patients.

Growing Regulatory Support and Accelerated Approvals

Global regulatory agencies are increasingly supporting RNA-based therapeutics through fast-track designations and adaptive approval pathways. The success of early RNA drugs has strengthened confidence in safety and efficacy frameworks. Governments are also funding RNA research to improve pandemic preparedness and chronic disease management. This regulatory encouragement shortens commercialization timelines and attracts new entrants into the market. The growing acceptance of RNA technology as a reliable therapeutic modality continues to open new investment and growth opportunities worldwide.

Key Challenges

High Manufacturing and Development Costs

RNA-based therapeutics involve complex synthesis, purification, and formulation processes that drive up production costs. Maintaining molecule stability during manufacturing and distribution remains technically challenging. Limited large-scale infrastructure and dependence on specialized materials further increase expenses. These high costs restrict accessibility, particularly in low- and middle-income regions. Companies are focusing on process optimization, automation, and scalable production models to overcome these cost barriers and make RNA-based treatments more commercially viable and globally available.

Delivery Efficiency and Off-Target Effects

Achieving safe and efficient delivery of RNA molecules remains a major hurdle. RNA strands are highly unstable and prone to degradation before reaching target cells. Additionally, unintended gene silencing can lead to safety concerns and unpredictable immune responses. Researchers are working to refine nanoparticle carriers and chemical modifications to enhance stability and tissue specificity. Ensuring consistent bioavailability and minimizing adverse reactions are critical to broadening clinical acceptance and sustaining long-term growth of antisense and RNAi therapeutics.

Regional Analysis

North America

North America held a 44.6% share of the antisense and RNAi therapeutics market in 2024, driven by strong R&D activity, advanced healthcare infrastructure, and favorable regulatory frameworks. The United States dominates the region with multiple FDA-approved RNA-based drugs and an extensive clinical pipeline targeting rare and genetic disorders. Growing investments from major biotechnology firms such as Ionis Pharmaceuticals and Alnylam strengthen the market’s innovation base. Supportive funding from the National Institutes of Health (NIH) and collaborations between academia and industry further boost drug development and adoption across various therapeutic areas.

Europe

Europe accounted for 29.3% of the global antisense and RNAi therapeutics market in 2024, supported by strong regulatory backing, innovation-driven pharmaceutical industries, and active clinical research across Germany, the United Kingdom, and France. The region benefits from EMA’s adaptive approval policies for RNA-based drugs and growing emphasis on personalized medicine. Increasing prevalence of rare diseases and expanding access to advanced genetic testing have accelerated therapy adoption. Leading biopharma companies are investing in partnerships and R&D programs to develop next-generation RNA therapeutics targeting cancer, neurological disorders, and infectious diseases.

Asia-Pacific

Asia-Pacific held a 20.8% share of the antisense and RNAi therapeutics market in 2024, emerging as the fastest-growing region due to increasing biotechnology investments and expanding healthcare infrastructure. China, Japan, and South Korea lead the region with strong government support for genomic research and RNA-based drug development. Rising awareness of rare genetic disorders and improving diagnostic capabilities drive market expansion. Partnerships between global pharmaceutical companies and regional biotech firms are enhancing access to advanced RNA therapies. Continuous innovation in nanoparticle delivery systems is further strengthening the region’s position in RNA medicine commercialization.

Latin America

Latin America captured a 3.2% share of the antisense and RNAi therapeutics market in 2024, driven by rising demand for advanced genetic treatments and expanding access to modern healthcare. Brazil and Mexico are leading contributors due to growing clinical trial participation and increasing collaborations with global biopharmaceutical companies. Government initiatives to strengthen biotechnology sectors and improve patient access to innovative therapies are fostering market growth. However, high treatment costs and limited regulatory infrastructure continue to challenge widespread adoption, prompting partnerships to improve affordability and local manufacturing capacity.

Middle East & Africa

The Middle East and Africa accounted for 2.1% of the global antisense and RNAi therapeutics market in 2024, supported by gradual expansion of healthcare systems and growing investment in precision medicine. The United Arab Emirates, Saudi Arabia, and South Africa are key markets focusing on genomic research and specialized treatment centers. International collaborations with Western pharmaceutical companies are enabling technology transfer and early access to clinical therapies. While the market is still nascent, increasing prevalence of chronic and genetic diseases and government-backed healthcare reforms are expected to drive future growth across the region.

Market Segmentations:

By Technology

• RNA Interference
• Antisense RNA

By Application

• Genetic Disease
• Cancer
• Infectious Disease
• Skin Disorders

By Route of Administration

• Intrathecal Injections
• Intravenous Injections
• Subcutaneous Injections
• Other Delivery Methods

 By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Competitive Landscape

The competitive landscape of the antisense and RNAi therapeutics market includes key players such as Ionis Pharmaceuticals, Inc., Olix Pharmaceuticals, Inc., Sanofi, Benitec Biopharma Inc., Percheron Therapeutics Limited, Alnylam Pharmaceuticals, Inc., GSK plc, Silence Therapeutics, Sarepta Therapeutics, and Arbutus Biopharma. These companies are actively developing novel RNA-based drugs targeting rare, genetic, and oncological disorders. Strategic collaborations, licensing agreements, and acquisitions are central to their growth strategies, helping to expand clinical pipelines and enhance delivery technologies. Ionis and Alnylam lead the market with multiple commercialized RNA therapeutics and strong late-stage portfolios. Meanwhile, emerging biotechs like Olix and Benitec focus on next-generation gene-silencing platforms. Large pharmaceutical players such as Sanofi and GSK are increasing their investments in RNA innovation through partnerships and joint development programs. Overall, competition is intensifying as companies aim to optimize RNA stability, delivery, and regulatory success for wider clinical adoption.

Key Player Analysis

• Ionis Pharmaceuticals, Inc.
• Olix Pharmaceuticals, Inc.
• Sanofi
  • Benitec Biopharma Inc.
  • Percheron Therapeutics Limited
• Alnylam Pharmaceuticals, Inc.
• GSK plc
• Silence Therapeutics
• Sarepta Therapeutics
• Arbutus Biopharma

Recent Developments

• In October 2025, Silence Therapeutics plc completed enrollment of 48 phlebotomy-dependent polycythemia vera (PV) patients in its SANRECO Phase 2 study of divesiran, a first-in-class siRNA targeting TMPRSS6.
• In August 2025, Alnylam announced it would present new data at the European Society of Cardiology (ESC) Congress 2025 on its investigational programs targeting hypertension and transthyretin amyloidosis, underscoring its advancing RNAi pipeline.
• In May 2024, Ionis Pharmaceuticals, Inc. and Biogen Inc. announced they would discontinue development of BIIB105 (ION541), an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), following topline results from their Phase 1/2 ALSpire study.
• In March 2025, Alnylam Pharmaceuticals, Inc. achieved U.S. FDA approval for Qfitlia™ (fitusiran), marking their sixth discovered RNAi therapeutic and the first to lower antithrombin (AT) to prevent bleeding episodes in patients with hemophilia A or B.

Report Coverage

The research report offers an in-depth analysis based on Technology, Application, Route of Administration and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

1. The antisense and RNAi therapeutics market will continue to grow rapidly due to strong clinical success rates.
2. Advancements in RNA delivery systems will enhance drug stability and expand therapeutic reach.
3. Increasing approvals for rare and genetic disease treatments will strengthen commercial adoption.
4. Partnerships between biotech firms and large pharmaceutical companies will accelerate product development.
5. Expansion into oncology and infectious disease applications will diversify revenue streams.
6. Regulatory agencies will provide faster approval pathways for innovative RNA-based therapies.
7. North America will remain the leading region, supported by advanced R&D and funding initiatives.
8. Asia-Pacific will witness the fastest growth due to rising biotech investments and government support.
9. The shift toward personalized and precision medicine will drive customized RNA therapy development.
10. Continued innovation in gene-silencing technologies will shape the next phase of molecular drug discovery.

Advancements in RNA-Based Drug Delivery Technologies

Innovations in lipid nanoparticles, conjugates, and viral vectors are improving the stability, bioavailability, and targeted delivery of RNA-based drugs, enabling broader therapeutic applications and accelerating clinical success.

Rising Prevalence of Genetic and Rare Diseases

The increasing incidence of hereditary and rare disorders is fueling demand for antisense and RNAi therapeutics, as these modalities offer precise molecular correction and benefit from regulatory incentives such as orphan drug designations.

Increased Investment and Strategic Collaborations

Pharmaceutical and biotech companies are forming partnerships and securing funding to expand RNA therapeutic pipelines, streamline clinical development, and enhance global manufacturing capacity, driving faster innovation and commercialization.

Expansion into Oncology and Infectious Diseases

RNA-based therapeutics are increasingly being developed for cancer and viral infections, leveraging gene-silencing capabilities to address unmet needs in oncology and infectious disease management, thus diversifying market opportunities.

Growing Regulatory Support and Accelerated Approvals

Regulatory agencies are providing fast-track and adaptive approval pathways for RNA-based drugs, shortening commercialization timelines and encouraging more companies to invest in RNAi and antisense platforms.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.